Cover Image
市場調查報告書

搭配診斷市場

Companion Diagnostics Markets (Cancer, Cardiovascular and Blood, Metabolic, Infection, Neurological and Others)

出版商 Kalorama Information 商品編碼 311712
出版日期 內容資訊 英文 298 Pages
訂單完成後即時交付
價格
Back to Top
搭配診斷市場 Companion Diagnostics Markets (Cancer, Cardiovascular and Blood, Metabolic, Infection, Neurological and Others)
出版日期: 2014年08月08日 內容資訊: 英文 298 Pages
簡介

搭配診斷的市場正在擴大中,許多醫藥品開發企業正在該領域致力於開發。近年來,以癌症治療領域為中心,許多搭配診斷藥投入市場,也引入一般診斷、治療計劃中。至今搭配診斷用檢查藥都尚未通過芙國食品藥品管理局(FDA)的認証,製藥公司也無法針對擴大普及率來積極推廣,導至市場滲透率毫無進展。但由於大家對搭配診斷可針對專治特定疾病的治療藥有效的患者、排除效果難以期待的患者,有助於降低醫療費用這個認知的擴大,讓醫療現場搭配診斷的重要性高升,以美國及歐洲企業為中心,打入市場的動作正在活絡化。

本報告在追蹤全球搭配診斷市場上新動向同時,更以2013∼2014年投入市場的產品為焦點,提供您癌症,循環系統和血液的疾病,代謝疾病,感染疾病,中樞神經系統疾病等五大領域上的產品分析與到2018年前的預測,更網羅主要企業簡介等資訊。

第1章 摘要整理

  • 概要
  • 調查範圍與手法
  • 整體市場規模與成長性
  • 影響市場的問題與趨勢
  • 競爭的主要企業

第2章 搭配診斷產業的簡介

  • 概要
  • 生物標記
  • 生物標記的類型
  • 治療方法選擇工具的生物標記
  • 治療監視工具的生物標記
  • 個人化醫療
  • 潛在的優點
  • 隱私和社會的認識

第3章 產業的趨勢

  • 保健產業
  • 人口動態
  • 平均壽命
  • 慢性疾病的影響
  • 疾病和高齡化
  • 美國的醫療改革
  • 共同開發和合作契約
  • 搭配診斷的經營模式
  • 給付的問題
  • 抗生素抗藥性
  • 金磚四國的參與
  • 法規結構
  • 分子檢驗費用的給付

第4章 搭配診斷產品

  • 癌症
  • 循環系統疾病
  • 內分泌疾病,自體免疫疾病
  • 感染疾病
  • 中樞神經系統疾病

第5章 市場規模與成長性

  • 市場課題
  • 市場概要
  • 各地區市場

第6章 主要企業簡介

  • 簡介
  • 20/20 GeneSystems, Inc.
  • Abbott Laboratories
  • Affymetrix
  • Agendia, Inc. USA
  • Alere, Inc
  • Asuragen, Inc.
  • Beckman Coulter, Inc
  • Becton, Dickinson
  • Biocartis S.A.
  • Biodesix, Inc.
  • bioMerieux SA
  • BioReference Laboratories, Inc
  • bioTheranostics, Inc.
  • CARDIODX, INC
  • CELERA ALAMEDA
  • Clarient, Inc
  • deCODE Genetics, Inc.
  • DiaGenic ASA
  • Genomic Health, Inc.
  • Genoptix Medical Laboratory
  • Illumina, Inc.
  • Johnson & Johnson
  • Life Technologies Corporation (Thermo Fisher旗下)
  • Memory Dx
  • Myriad Genetics, Inc.
  • Nanostring Technologies, Inc.
  • OPKO Health, Inc.
  • Provista Dx
  • Qiagen N.V.
  • Roche
  • SIEMENS HEALTHCARE
  • Singulex, Inc
  • Thermo Fisher Scientific

附錄

目錄
Product Code: KLI5310061

The global companion diagnostic market is on the rise, and companion diagnostic development is becoming a primary area of focus for pharmaceutical developers. Many companion diagnostics are now successfully marketed, mainly in the cancer segment, with several of them part of a routine diagnostic and treatment plan.

This report tracks these developments and provides detailed examples of drug-test pairs. It also provides market estimation and forecast models for business planning.

There had been a slow market uptake of companion diagnostics because companion tests lacked FDA approval, which prevented pharmaceutical companies from promoting the diagnostic. But the realization that companion diagnostics can decrease costs by identifying the patient population that will most likely benefit from a therapy and ruling out those therapies not likely to be effective has made companion diagnostics important to the delivery of care.

This report, Companion Diagnostics Markets tracks these new developments and focuses on companion diagnostics in medicine in 2013 and 2014. The report provides product analysis for the five broad areas of medical companion diagnostics and market information:

  • Cancer
  • Cardiovascular and Blood
  • Metabolic
  • Infection
  • Neurological
  • Market Size by Disease Area, 2013 and 2018

Companion diagnostics have met with considerable challenges in penetrating the market, but are now rising to the forefront of pharmaceutical development and treatment, increasing the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics and biomarkers provide insight into understanding disease processes and ways that medicines can work to counteract the disease.

The majority of competitive participation for companion diagnostics is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market which include large multiproduct companies such as Roche and Abbott and small niche developers such as 20/20 GeneSystems.

Companies profiles in this report include:

  • 20/20 GeneSystems
  • Abbott Laboratories
  • Affymetrix
  • Agendia
  • Alere
  • Beckman Coulter
  • Becton Dickinson
  • Biocartis SA
  • Biodesix
  • bioMerieux
  • BioReference Laboratory
  • bioTheranostics
  • CardioDX
  • Celera Alameda
  • Clarient
  • deCODE Genetics
  • DiaGenic
  • Genomic Health
  • Genoptix Medical Laboratory
  • Illumina
  • Johnson & Johnson
  • Life Techologies
  • Memory Dx
  • Myriad Genetics
  • Nanostring Technologies
  • OPKO Health
  • Provista Dx
  • Qiagen
  • Roche
  • Seimens Healthcare
  • Singulex
  • Thermo Fisher Scientific

The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.

All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers' level. The base year for data was 2013. Historical data was provided for the years 2011 through 2013, with forecast data provided for 2014 through 2018. Compound annual growth rates (CAGRs) are provided for the 2011-2013 and 2013-2018 periods for each segment covered. Basic competitor summaries are included in each segment. The forecasted market analysis for 2013-2018 was largely based on demographic trends, new developments, biomarker development, companion diagnostic deals, company performance trends, merger and acquisitions, and global expansion.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Overview
  • Scope and Methodology
  • Total Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

TWO: INTRODUCTION TO THE COMPANION DIAGNOSTICS INDUSTRY

  • Overview
  • Biomarkers
  • Types of Biomarkers
  • Biomarkers as Treatment Selection Tool
  • Biomarkers as Therapy Monitoring Tool
  • Personalized Medicine
  • Potential Benefits
  • Privacy and Public Perception

THREE: INDUSTRY TRENDS

  • The Health Industry
  • Population Demographics
  • Life Expectancy
  • Chronic Disease Impact
  • Disease and An Aging Population
  • Healthcare Reform in the United States
  • Co-Development and Partnership Deals
  • Companion Diagnostic Business Model
  • Reimbursement Issues
  • Antimicrobial Drug Resistance
  • BRIC Involvement
  • Regulatory Structure
  • Molecular Test Reimbursement

FOUR: COMPANION DIAGNOSTIC PRODUCTS

  • Cancer
  • Overview
  • Biochemistry of Cancer Cells
  • Carcinogen Metabolism
  • Causes of Cancer Growth
  • Environmental Factors, DNA, RNA
  • Cellular Oncogenes
  • Tumor Suppressor Genes
  • History of Cancer
  • Cancer Types
  • Cancer Biomarker Examples
  • New Developments
  • Cancer Companion Diagnostics
  • Selected Cancer Companion Diagnostics in Development
  • Cardiovascular
  • Overview
  • The Cardiovascular System
  • Heart
  • Circulatory System
  • Cardiac Cycle
  • Coronary Circulation
  • Cardiac Myocytes
  • Molecular Contraction
  • Cardiovascular and Blood Diseases
  • Ischemic Heart Disease
  • Chronic Ischemic Cardiomyopathy
  • Sudden Cardiac Death
  • Valvular and Endocardial Diseases
  • Mitral Valve Disorders
  • Aortic Valve Disorders
  • Rheumatic Heart Disease
  • Endocarditis
  • Pericardial Diseases
  • Pericardial Effusion
  • Pericarditis
  • Myocardial Diseases
  • Myocarditis
  • Cardiomyopathy
  • Congenital Heart Diseases
  • Atrial Septal Defect
  • Ventral Septal Defect
  • Pulmonary Stenosis
  • Aortic Stenosis
  • Coarctation of the Aorta
  • Patent Ductus Arteriosus
  • Truncus Arteriosus
  • Transposition of the Great Arteries
  • Tricuspid Atresia
  • Congestive Heart Failure
  • Etiology
  • Cardiac Dysrhythmias
  • Hypertension
  • Risk Factors
  • Effects of High Blood Pressure
  • Blood Disorders
  • Hyperlipidemia
  • Biomarker Availability
  • New Developments
  • Companion Diagnostics
  • Selected Cardiovascular Companion Diagnostics in Development
  • Endocrine, Autoimmune
  • Overview
  • The Endocrine System
  • Hormone Function
  • Hormone Synthesis
  • Immune System
  • Autoimmunity
  • Genetic Factors
  • Environmental Factors
  • Inflammatory Disorders
  • Disease Overview
  • Classification of Endocrine Disorders
  • Growth Hormone Disorders
  • 1Etiology of Growth Hormone
  • Antidiuretic Hormone Disorders
  • Etiology
  • Thyroid Hormone Disorders
  • Hypothyroidism
  • Hyperthyroidism
  • Adrenocortical Hormone Disorders
  • Diabetes Mellitus
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Rheumatic Arthritis
  • Biomarker Availability
  • New Developments
  • Companion Diagnostics
  • Infectious Disease
  • Overview
  • Infection
  • Infectious Diseases
  • HIV Disease
  • Hepatitis C
  • Human Papillomavirus (HPV)
  • Sepsis
  • Biomarker Availability
  • New Developments
  • Companion Diagnostics
  • Central Nervous System
  • Overview
  • The Nervous System
  • Central Nervous System
  • Peripheral Nervous System
  • Autonomic Nervous System
  • Nervous System Disorders
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Stroke
  • Biomarker Examples
  • New Developments
  • Companion Diagnostics

FIVE: MARKET SIZE AND GROWTH

  • Market Considerations
  • Market Overview
  • Companion Diagnostics Market by Geographical Region

SIX: COMPANY PROFILES

  • Introduction
  • 20/20 GeneSystems, Inc.
  • Company Overview
  • Abbott Laboratories
  • Company Overview
  • Affymetrix
  • Company Overview
  • Agendia, Inc. USA
  • Company Overview
  • Alere, Inc
  • Company Overview
  • Asuragen, Inc.
  • Company Overview
  • Beckman Coulter, Inc
  • Company Overview
  • Becton, Dickinson
  • Company Overview
  • Biocartis S.A.
  • Company Overview
  • Biodesix, Inc.
  • Company Overview
  • bioMerieux SA
  • Company Overview
  • BioReference Laboratories, Inc
  • Company Overview
  • bioTheranostics, Inc.
  • Company Overview
  • CARDIODX, INC
  • Company Overview
  • CELERA ALAMEDA
  • Company Overview
  • Clarient, Inc
  • Company Overview
  • deCODE Genetics, Inc.
  • Company Overview
  • DiaGenic ASA
  • Company Overview
  • Genomic Health, Inc.
  • Company Overview
  • Genoptix Medical Laboratory
  • Company Overview
  • Illumina, Inc.
  • Company Overview
  • Johnson & Johnson
  • Company Overview
  • Life Technologies Corporation (part of Thermo Fisher)
  • Company Overview
  • Memory Dx
  • Company Overview
  • Myriad Genetics, Inc.
  • Company Overview
  • Nanostring Technologies, Inc.
  • Company Overview
  • OPKO Health, Inc.
  • Company Overview
  • Provista Dx
  • Company Overview
  • Qiagen N.V.
  • Company Overview
  • Roche
  • Company Overview
  • SIEMENS HEALTHCARE
  • Company Overview
  • Singulex, Inc
  • Company Overview
  • Thermo Fisher Scientific
  • Company Overview

APPENDIX: LIST OF CONTRIBUTORS

Back to Top